Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHA:603139)
China · Delayed Price · Currency is CNY 39.17
+1.29 (3.41%)
Jun 11, 2026, 2:15 PM CST
SHA:603139 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 431.44 | 459.44 | 544.4 | 664.59 | 487.17 | 441.42 |
Other Revenue | 11.85 | 11.85 | 17.23 | 8.37 | 4.35 | 1.33 |
| 443.29 | 471.29 | 561.63 | 672.96 | 491.51 | 442.76 | |
Revenue Growth (YoY) | -20.22% | -16.09% | -16.54% | 36.92% | 11.01% | 6.93% |
Cost of Revenue | 352.61 | 382.6 | 405.9 | 489.21 | 303.02 | 241.87 |
Gross Profit | 90.68 | 88.69 | 155.73 | 183.75 | 188.49 | 200.88 |
Selling, General & Admin | 189.17 | 187.47 | 195.1 | 165.34 | 172.36 | 167.11 |
Research & Development | 13.53 | 12.15 | 8.32 | 10.98 | 12.35 | 10.15 |
Other Operating Expenses | 8.62 | 8.03 | 7.37 | 5.23 | 3.17 | 3.65 |
Operating Expenses | 227.45 | 224.09 | 216.7 | 182.38 | 196.66 | 182.61 |
Operating Income | -136.77 | -135.4 | -60.97 | 1.37 | -8.17 | 18.27 |
Interest Expense | -33.62 | -34.34 | -34.79 | -23.46 | -13.22 | -6.32 |
Interest & Investment Income | 0.65 | 1.03 | 2.72 | 5.32 | 5.62 | 17.21 |
Other Non Operating Income (Expenses) | -4.88 | -5.35 | 0.78 | -4.02 | -1.23 | -1.78 |
EBT Excluding Unusual Items | -174.62 | -174.06 | -92.27 | -20.78 | -17 | 27.38 |
Impairment of Goodwill | -7.62 | -7.62 | - | - | -4.87 | - |
Gain (Loss) on Sale of Investments | -8.33 | -8.33 | -31.15 | -28.74 | -54.83 | 9.47 |
Gain (Loss) on Sale of Assets | 42.37 | -0.31 | 0.16 | 0.05 | -6.68 | - |
Asset Writedown | -150.96 | -157.72 | -1.2 | -16.86 | - | -0.01 |
Other Unusual Items | 6.69 | 4.65 | 2.92 | 8.38 | 0.63 | 1.75 |
Pretax Income | -292.48 | -343.39 | -121.54 | -57.94 | -82.74 | 38.59 |
Income Tax Expense | -5.45 | -7.04 | -9.54 | -7.17 | -5.96 | 5.59 |
Earnings From Continuing Operations | -287.02 | -336.35 | -112 | -50.78 | -76.78 | 33 |
Minority Interest in Earnings | -8.31 | 2.89 | 22.37 | 24.62 | 13.73 | 3.48 |
Net Income | -295.33 | -333.45 | -89.63 | -26.16 | -63.06 | 36.48 |
Net Income to Common | -295.33 | -333.45 | -89.63 | -26.16 | -63.06 | 36.48 |
Net Income Growth | - | - | - | - | - | 6.94% |
Shares Outstanding (Basic) | 99 | 100 | 100 | 101 | 100 | 99 |
Shares Outstanding (Diluted) | 99 | 100 | 100 | 101 | 100 | 99 |
Shares Change (YoY) | 1.60% | 0.25% | -1.02% | 0.52% | 1.51% | -1.73% |
EPS (Basic) | -2.97 | -3.34 | -0.90 | -0.26 | -0.63 | 0.37 |
EPS (Diluted) | -2.97 | -3.34 | -0.90 | -0.26 | -0.63 | 0.37 |
EPS Growth | - | - | - | - | - | 8.82% |
Free Cash Flow | -6.32 | -32.25 | -9.37 | -144.52 | -87.7 | -282.88 |
Free Cash Flow Per Share | -0.06 | -0.32 | -0.09 | -1.44 | -0.88 | -2.87 |
Dividend Per Share | - | - | - | - | - | 0.074 |
Dividend Growth | - | - | - | - | - | 5.71% |
Gross Margin | 20.46% | 18.82% | 27.73% | 27.30% | 38.35% | 45.37% |
Operating Margin | -30.85% | -28.73% | -10.86% | 0.20% | -1.66% | 4.13% |
Profit Margin | -66.62% | -70.75% | -15.96% | -3.89% | -12.83% | 8.24% |
Free Cash Flow Margin | -1.43% | -6.84% | -1.67% | -21.48% | -17.84% | -63.89% |
EBITDA | -70.13 | -70.3 | -2.07 | 38.21 | 17.18 | 34.64 |
EBITDA Margin | -15.82% | -14.92% | -0.37% | 5.68% | 3.50% | 7.82% |
D&A For EBITDA | 66.64 | 65.09 | 58.9 | 36.83 | 25.34 | 16.37 |
EBIT | -136.77 | -135.4 | -60.97 | 1.37 | -8.17 | 18.27 |
EBIT Margin | -30.85% | -28.73% | -10.86% | 0.20% | -1.66% | 4.13% |
Effective Tax Rate | - | - | - | - | - | 14.49% |
Revenue as Reported | 443.29 | 471.29 | 561.63 | 672.96 | 491.51 | 442.76 |
Advertising Expenses | - | 1.44 | 3.86 | - | - | - |